FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152750473> ?p ?o ?g. }

• W3152750473 endingPage "664" @default.
• W3152750473 startingPage "655" @default.
• W3152750473 abstract "Background The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43–0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint. Methods This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with previously untreated histologically confirmed stage IIIA, IIIB, or IIIC resected cutaneous melanoma, and an Eastern Cooperative Oncology Group performance status score of 1 or 0 were eligible. Patients were randomly assigned (1:1) using a central interactive voice-response system on the basis of a minimisation technique stratified for stage and geographic region to receive intravenously 200 mg pembrolizumab or placebo. Treatment was administered every 3 weeks for 1 year, or until disease recurrence, unacceptable toxicity, or death. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, with global health/quality of life (GHQ) over 2 years measured by the EORTC QLQ-C30 as the primary analysis. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37, and long-term follow-up is ongoing. Findings Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to pembrolizumab (n=514) or placebo (n=505). Median follow-up was 15·1 months (IQR 12·8–16·9) at the time of this analysis. HRQOL compliance was greater than 90% at baseline, greater than 70% during the first year, and greater than 60% thereafter for both groups. Because of low absolute compliance numbers at later follow-up, the analysis was truncated to week 84. Baseline GHQ scores were similar between groups (77·55 [SD 18·20] in the pembrolizumab group and 76·54 [17·81] in the placebo group) and remained stable over time. The difference in average GHQ score between the two groups over the 2 years was −2·2 points (95% CI −4·3 to −0·2). The difference in average score during treatment was −1·1 points (95% CI −3·2 to 0·9) and the difference in average score after treatment was −2·2 points (−4·8 to 0·4). These differences are within the 5-point clinical relevance threshold for the QLQ-C30 and are therefore clinically non-significant. Interpretation Pembrolizumab does not result in a clinically significant decrease in HRQOL compared with placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. Funding Merck Sharp & Dohme." @default.
• W3152750473 created "2021-04-26" @default.
• W3152750473 creator A5000291176 @default.
• W3152750473 creator A5000993397 @default.
• W3152750473 creator A5001548963 @default.
• W3152750473 creator A5001893646 @default.
• W3152750473 creator A5004262252 @default.
• W3152750473 creator A5004458225 @default.
• W3152750473 creator A5004497401 @default.
• W3152750473 creator A5005521408 @default.
• W3152750473 creator A5007525817 @default.
• W3152750473 creator A5007887862 @default.
• W3152750473 creator A5007925131 @default.
• W3152750473 creator A5008284375 @default.
• W3152750473 creator A5009498566 @default.
• W3152750473 creator A5010492722 @default.
• W3152750473 creator A5011037498 @default.
• W3152750473 creator A5012911914 @default.
• W3152750473 creator A5013384569 @default.
• W3152750473 creator A5013963200 @default.
• W3152750473 creator A5015081105 @default.
• W3152750473 creator A5016161312 @default.
• W3152750473 creator A5018131884 @default.
• W3152750473 creator A5018519159 @default.
• W3152750473 creator A5018536695 @default.
• W3152750473 creator A5019573174 @default.
• W3152750473 creator A5020064368 @default.
• W3152750473 creator A5021075431 @default.
• W3152750473 creator A5022449574 @default.
• W3152750473 creator A5023376896 @default.
• W3152750473 creator A5024957157 @default.
• W3152750473 creator A5025478490 @default.
• W3152750473 creator A5026967523 @default.
• W3152750473 creator A5028034211 @default.
• W3152750473 creator A5028637754 @default.
• W3152750473 creator A5029177202 @default.
• W3152750473 creator A5029398339 @default.
• W3152750473 creator A5031394337 @default.
• W3152750473 creator A5031777632 @default.
• W3152750473 creator A5031791085 @default.
• W3152750473 creator A5031995998 @default.
• W3152750473 creator A5032262791 @default.
• W3152750473 creator A5033258883 @default.
• W3152750473 creator A5033330872 @default.
• W3152750473 creator A5034014576 @default.
• W3152750473 creator A5034365278 @default.
• W3152750473 creator A5034402801 @default.
• W3152750473 creator A5036706022 @default.
• W3152750473 creator A5036818390 @default.
• W3152750473 creator A5037357027 @default.
• W3152750473 creator A5037399273 @default.
• W3152750473 creator A5037516725 @default.
• W3152750473 creator A5037620517 @default.
• W3152750473 creator A5039327042 @default.
• W3152750473 creator A5039970331 @default.
• W3152750473 creator A5041302754 @default.
• W3152750473 creator A5042518844 @default.
• W3152750473 creator A5042724544 @default.
• W3152750473 creator A5044024585 @default.
• W3152750473 creator A5044736874 @default.
• W3152750473 creator A5047774887 @default.
• W3152750473 creator A5047916486 @default.
• W3152750473 creator A5049885447 @default.
• W3152750473 creator A5050034324 @default.
• W3152750473 creator A5050537086 @default.
• W3152750473 creator A5050952919 @default.
• W3152750473 creator A5051355971 @default.
• W3152750473 creator A5052208505 @default.
• W3152750473 creator A5052339496 @default.
• W3152750473 creator A5052572303 @default.
• W3152750473 creator A5054331333 @default.
• W3152750473 creator A5054723003 @default.
• W3152750473 creator A5055038393 @default.
• W3152750473 creator A5055627811 @default.
• W3152750473 creator A5055983682 @default.
• W3152750473 creator A5056132643 @default.
• W3152750473 creator A5056290263 @default.
• W3152750473 creator A5056685282 @default.
• W3152750473 creator A5056705823 @default.
• W3152750473 creator A5056723192 @default.
• W3152750473 creator A5057991836 @default.
• W3152750473 creator A5058635134 @default.
• W3152750473 creator A5058938160 @default.
• W3152750473 creator A5059674386 @default.
• W3152750473 creator A5059800915 @default.
• W3152750473 creator A5061072132 @default.
• W3152750473 creator A5061157288 @default.
• W3152750473 creator A5063123624 @default.
• W3152750473 creator A5063850381 @default.
• W3152750473 creator A5064026461 @default.
• W3152750473 creator A5064052929 @default.
• W3152750473 creator A5065930194 @default.
• W3152750473 creator A5066544866 @default.
• W3152750473 creator A5066790760 @default.
• W3152750473 creator A5066911633 @default.
• W3152750473 creator A5067776208 @default.
• W3152750473 creator A5067814311 @default.
• W3152750473 creator A5068079253 @default.

• next